In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Analysts have set 12-month price targets for Teva Pharmaceutical Indus, revealing an average target of $23.75, a high estimate of $26.00, and a low estimate of $22.00. This upward trend is apparent, with the current average reflecting a 10.47% increase from the previous average price targ…